LU93049I2 - Susoctocog - Google Patents
Susoctocog Download PDFInfo
- Publication number
- LU93049I2 LU93049I2 LU93049C LU93049C LU93049I2 LU 93049 I2 LU93049 I2 LU 93049I2 LU 93049 C LU93049 C LU 93049C LU 93049 C LU93049 C LU 93049C LU 93049 I2 LU93049 I2 LU 93049I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- factor viii
- inhibitory antibodies
- amino acid
- modified factor
- loci
- Prior art date
Links
- 102000001690 Factor VIII Human genes 0.000 abstract 4
- 108010054218 Factor VIII Proteins 0.000 abstract 4
- 229960000301 factor viii Drugs 0.000 abstract 4
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 102000002110 C2 domains Human genes 0.000 abstract 1
- 108050009459 C2 domains Proteins 0.000 abstract 1
- 208000031220 Hemophilia Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 102000057593 human F8 Human genes 0.000 abstract 1
- 229960000900 human factor viii Drugs 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/10—Factor VIII, AHF; related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Glass Compositions (AREA)
- Fish Paste Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/523,656 US6458563B1 (en) | 1996-06-26 | 2000-03-10 | Modified factor VIII |
| PCT/US2001/005076 WO2001068109A1 (en) | 2000-03-10 | 2001-02-16 | Modified factor viii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU93049I2 true LU93049I2 (fr) | 2016-06-27 |
Family
ID=24085870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU93049C LU93049I2 (fr) | 2000-03-10 | 2016-04-27 | Susoctocog |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US6458563B1 (OSRAM) |
| EP (1) | EP1280540B1 (OSRAM) |
| JP (1) | JP4044337B2 (OSRAM) |
| KR (1) | KR100485525B1 (OSRAM) |
| CN (1) | CN1191360C (OSRAM) |
| AT (1) | ATE391512T1 (OSRAM) |
| AU (2) | AU3841601A (OSRAM) |
| BE (1) | BE2016C024I2 (OSRAM) |
| BR (2) | BRPI0109131B8 (OSRAM) |
| CA (1) | CA2400295C (OSRAM) |
| CY (2) | CY1108179T1 (OSRAM) |
| CZ (1) | CZ298250B6 (OSRAM) |
| DE (1) | DE60133541T2 (OSRAM) |
| DK (1) | DK1280540T3 (OSRAM) |
| EE (1) | EE05075B1 (OSRAM) |
| ES (1) | ES2304379T3 (OSRAM) |
| FR (1) | FR16C0016I2 (OSRAM) |
| HU (2) | HU227804B1 (OSRAM) |
| IL (2) | IL151371A0 (OSRAM) |
| LT (1) | LTC1280540I2 (OSRAM) |
| LU (1) | LU93049I2 (OSRAM) |
| ME (1) | MEP8209A (OSRAM) |
| MX (1) | MXPA02008798A (OSRAM) |
| NL (1) | NL300808I2 (OSRAM) |
| NO (2) | NO331935B1 (OSRAM) |
| NZ (1) | NZ520799A (OSRAM) |
| PL (1) | PL202936B1 (OSRAM) |
| PT (1) | PT1280540E (OSRAM) |
| RS (1) | RS50364B (OSRAM) |
| RU (1) | RU2285724C2 (OSRAM) |
| SI (1) | SI1280540T1 (OSRAM) |
| SK (1) | SK286205B6 (OSRAM) |
| UA (1) | UA75064C2 (OSRAM) |
| WO (1) | WO2001068109A1 (OSRAM) |
| ZA (1) | ZA200206810B (OSRAM) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560107B2 (en) | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
| JP2005518181A (ja) * | 2001-01-12 | 2005-06-23 | ジ・アメリカン・ナショナル・レッド・クロス | 第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物 |
| JP4634036B2 (ja) * | 2001-10-05 | 2011-02-16 | エクスプレッション セラピューティクス， エルエルシー | 高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法 |
| AU2002364509A1 (en) * | 2001-11-30 | 2003-06-17 | Emory University | Factor viii c2 domain variants |
| GB0207092D0 (en) * | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7498024B2 (en) * | 2003-06-03 | 2009-03-03 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site |
| US7485291B2 (en) * | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| WO2005000891A2 (en) * | 2003-06-26 | 2005-01-06 | Merck Patent Gmbh | Thrombopoietin proteins with improved properties |
| US20050059023A1 (en) * | 2003-09-16 | 2005-03-17 | Cantor Thomas L. | Methods and kits for monitoring resistance to therapeutic agents |
| US7211559B2 (en) * | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| ATE463572T1 (de) * | 2003-12-03 | 2010-04-15 | Univ Rochester | Rekombinanter faktor viii mit erhöhter spezifischer aktivität |
| DK1750733T3 (da) * | 2004-05-03 | 2014-01-20 | Univ Emory | FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII |
| WO2005123928A1 (en) * | 2004-06-08 | 2005-12-29 | Battelle Memorial Institute | Production of human coagulation factor viii from plant cells and whole plants |
| SI2363414T1 (sl) * | 2004-11-12 | 2022-09-30 | Bayer Healthcare Llc | Usmerjena modifikacija FVIII |
| WO2006063031A2 (en) * | 2004-12-06 | 2006-06-15 | Haplomics | Allelic variants of human factor viii |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| CN101379077A (zh) | 2005-12-07 | 2009-03-04 | 夏洛特·豪泽 | 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体 |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| WO2007115724A2 (en) * | 2006-04-11 | 2007-10-18 | Csl Behring Gmbh | Method of increasing the in vivo recovery of therapeutic polypeptides |
| US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| EP1935430A1 (en) * | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| AU2007338298B2 (en) * | 2006-12-22 | 2013-02-07 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| FR2913020B1 (fr) * | 2007-02-23 | 2012-11-23 | Biomethodes | Nouveaux facteurs viii pour le traitement des hemophiles de type a |
| EP1988101A1 (en) | 2007-05-04 | 2008-11-05 | Novo Nordisk A/S | Improvement of factor VIII polypeptide titers in cell cultures |
| CN101965409A (zh) * | 2007-11-01 | 2011-02-02 | 罗切斯特大学 | 具有增加的稳定性的重组因子viii |
| EP2149603A1 (en) | 2008-07-28 | 2010-02-03 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders |
| US20110046060A1 (en) | 2009-08-24 | 2011-02-24 | Amunix Operating, Inc., | Coagulation factor IX compositions and methods of making and using same |
| ES2730800T3 (es) | 2009-02-03 | 2019-11-12 | Amunix Pharmaceuticals Inc | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| DK2440239T3 (en) | 2009-06-09 | 2017-10-16 | Prolong Pharmaceuticals Llc | HEMOGLOBIN FORMATIONS |
| WO2011060371A2 (en) * | 2009-11-13 | 2011-05-19 | Puget Sound Blood Center | Factor viii t cell epitope variants having reduced immunogenicity |
| EP4382170A3 (en) | 2009-12-06 | 2024-09-04 | Bioverativ Therapeutics Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
| US20110177107A1 (en) * | 2010-01-14 | 2011-07-21 | Haplomics, Inc. | Predicting and reducing alloimmunogenicity of protein therapeutics |
| DK2591099T3 (da) | 2010-07-09 | 2021-02-15 | Bioverativ Therapeutics Inc | Kimære koagulationsfaktorer |
| WO2012006623A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Systems for factor viii processing and methods thereof |
| WO2012061689A2 (en) * | 2010-11-05 | 2012-05-10 | Ipsen Pharma S.A.S. | A new variant of antihemophilic factor viii having increased specific activity |
| JP2014504870A (ja) * | 2011-01-05 | 2014-02-27 | エクスプレッション セラピューティクス， エルエルシー | 高収率懸濁細胞株、システム、およびその製造方法 |
| PT2717898T (pt) | 2011-06-10 | 2019-05-20 | Bioverativ Therapeutics Inc | Compostos pró-coagulantes e processos para a sua utilização |
| AU2012282875B2 (en) | 2011-07-08 | 2016-04-21 | Bioverativ Therapeutics Inc. | Factor VIII chimeric and hybrid polypeptides, and methods of use thereof |
| EP2737311B1 (en) | 2011-07-25 | 2020-12-02 | Bioverativ Therapeutics Inc. | Assays to monitor bleeding disorders |
| CN102277379B (zh) * | 2011-08-18 | 2013-07-24 | 中国科学院遗传与发育生物学研究所 | 表达凝血因子viii的表达载体及其应用 |
| ES2753124T3 (es) | 2012-01-12 | 2020-04-07 | Bioverativ Therapeutics Inc | Polipéptidos quiméricos de factor VIII y usos de los mismos |
| ES2700583T3 (es) | 2012-01-12 | 2019-02-18 | Bioverativ Therapeutics Inc | Procedimientos para reducir la inmunogenicidad contra el Factor VIII en individuos sometidos a terapia con Factor VIII |
| EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| DK2814840T3 (da) | 2012-02-15 | 2020-02-03 | Bioverativ Therapeutics Inc | Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf |
| EP2666782A1 (en) * | 2012-05-22 | 2013-11-27 | Imnate Sarl | Coagulation factor VIII with reduced immunogenicity. |
| WO2013185113A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Procoagulant compounds |
| HK1207591A1 (en) | 2012-06-08 | 2016-02-05 | Biogen Ma Inc. | Chimeric clotting factors |
| US10023628B2 (en) | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
| DK2882450T3 (da) | 2012-07-11 | 2020-02-24 | Bioverativ Therapeutics Inc | Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf |
| US10001495B2 (en) | 2012-07-25 | 2018-06-19 | Bioverativ Therapeutics Inc. | Blood factor monitoring assay and uses thereof |
| WO2014063108A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
| EP3943102A1 (en) | 2012-10-30 | 2022-01-26 | Bioverativ Therapeutics Inc. | Methods of using fviii polypeptide |
| EP2928303A4 (en) | 2012-12-07 | 2016-07-13 | Haplomics Inc | FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION |
| FI2956477T4 (fi) | 2013-02-15 | 2024-04-24 | Bioverativ Therapeutics Inc | Optimoitu tekijä viii:n geeni |
| TWI828269B (zh) | 2013-03-15 | 2024-01-01 | 美商百歐維拉提夫治療公司 | 因子ix多肽調配物 |
| EP4122487A1 (en) | 2013-03-15 | 2023-01-25 | Bioverativ Therapeutics Inc. | Factor viii polypeptide formulations |
| MX2015016567A (es) | 2013-06-28 | 2016-03-31 | Biogen Ma Inc | Enlazador escindible por trombina con xten y usos del mismo. |
| US10947269B2 (en) | 2013-08-08 | 2021-03-16 | Bioverativ Therapeutics Inc. | Purification of chimeric FVIII molecules |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| EP3060242A1 (en) | 2013-10-22 | 2016-08-31 | DBV Technologies | Method of treating haemophilia by inducing tolerance to blood factors |
| US10584147B2 (en) | 2013-11-08 | 2020-03-10 | Biovertiv Therapeutics Inc. | Procoagulant fusion compound |
| EP4332839A3 (en) | 2013-12-06 | 2024-06-05 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
| EP2881463A1 (en) | 2013-12-09 | 2015-06-10 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders |
| CA2935954A1 (en) | 2014-01-10 | 2015-07-16 | Biogen Ma Inc. | Factor viii chimeric proteins and uses thereof |
| US20160347787A1 (en) | 2014-02-04 | 2016-12-01 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| US20170051041A1 (en) * | 2014-02-19 | 2017-02-23 | Kathleen Pratt | Factor viii b cell epitope variants having reduced immunogenicity |
| WO2015132724A1 (en) | 2014-03-05 | 2015-09-11 | Pfizer Inc. | Improved muteins of clotting factor viii |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
| TWI741992B (zh) | 2015-08-03 | 2021-10-11 | 美商百歐維拉提夫治療公司 | 因子ｉｘ融合蛋白以及其製備及使用方法 |
| PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| MY205187A (en) | 2015-11-13 | 2024-10-04 | Takeda Pharmaceuticals Co | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
| SG11201804070XA (en) | 2015-11-13 | 2018-06-28 | Baxalta Inc | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
| NZ745831A (en) | 2016-02-01 | 2025-07-25 | Bioverativ Therapeutics Inc | Optimized factor viii genes |
| EP3476937A4 (en) | 2016-06-24 | 2019-12-04 | Mogam Institute for Biomedical Research | CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF |
| KR20240069834A (ko) | 2016-12-02 | 2024-05-20 | 바이오버라티브 테라퓨틱스 인크. | 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법 |
| EP3548063A1 (en) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
| CA3063204A1 (en) | 2017-05-09 | 2018-11-15 | Emory University | Clotting factor variants and their use |
| US12168776B2 (en) | 2017-08-09 | 2024-12-17 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
| US20210038744A1 (en) | 2018-02-01 | 2021-02-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor viii |
| KR20210005608A (ko) | 2018-04-04 | 2021-01-14 | 시질론 테라퓨틱스, 인크. | 이식 가능한 입자 및 관련 방법 |
| CN112512555A (zh) | 2018-05-18 | 2021-03-16 | 比奥维拉迪维治疗股份有限公司 | 治疗血友病a的方法 |
| US12091675B2 (en) | 2018-07-16 | 2024-09-17 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression |
| MX2021001599A (es) | 2018-08-09 | 2021-07-02 | Bioverativ Therapeutics Inc | Moleculas de acido nucleico y sus usos para la terapia genica no viral. |
| UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
| TWI851647B (zh) | 2019-01-16 | 2024-08-11 | 日商武田藥品工業股份有限公司 | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體 |
| CA3144630A1 (en) | 2019-06-19 | 2020-12-24 | Bioverativ Therapeutics Inc. | Methods and compositions for treating hemophilia and low bone mineral density with factor viiifc protein |
| CN114375205A (zh) | 2019-06-20 | 2022-04-19 | 武田药品工业株式会社 | 用基于病毒的基因疗法进行治疗的方法 |
| TW202126284A (zh) | 2019-09-30 | 2021-07-16 | 美商百歐維拉提夫治療公司 | 慢病毒載體配製物 |
| WO2021119357A2 (en) | 2019-12-12 | 2021-06-17 | Baxalta Incorporated | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
| TW202208619A (zh) | 2020-06-24 | 2022-03-01 | 美商百歐維拉提夫治療公司 | 用於純化病毒載體之方法 |
| TW202246505A (zh) * | 2021-03-05 | 2022-12-01 | 俄羅斯聯邦商亞那拜恩有限公司 | 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途 |
| US11906532B2 (en) | 2021-03-31 | 2024-02-20 | Haemonetics Corporation | Hemostasis measurement device quality control formulations |
| US20240269241A1 (en) | 2021-06-14 | 2024-08-15 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
| WO2023028456A1 (en) | 2021-08-23 | 2023-03-02 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
| MX2024003963A (es) | 2021-09-30 | 2024-04-29 | Bioverativ Therapeutics Inc | Acidos nucleicos que codifican polipeptidos factor viii con inmunogenia reducida. |
| EP4602155A1 (en) | 2022-10-11 | 2025-08-20 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
| WO2025008774A1 (en) | 2023-07-05 | 2025-01-09 | Takeda Pharmaceutical Company Limited | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| EP0182448A3 (en) | 1984-08-24 | 1987-10-28 | Genetics Institute, Inc. | Production of factor viii and related products |
| WO1986006101A1 (en) * | 1985-04-12 | 1986-10-23 | Genetics Institute, Inc. | Novel procoagulant proteins |
| JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体 |
| DK162233C (da) | 1989-11-09 | 1992-03-16 | Novo Nordisk As | Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii |
| EP0737746A3 (en) * | 1989-12-01 | 1996-10-23 | Pharming B.V. | Production of recombinant polypeptides by bovine species and transgenic methods |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5663060A (en) | 1992-04-07 | 1997-09-02 | Emory University | Hybrid human/animal factor VIII |
| US6180371B1 (en) * | 1996-06-26 | 2001-01-30 | Emory University | Modified factor VIII |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| WO1997003191A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains |
| AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| EP1319016A4 (en) * | 2000-09-19 | 2006-05-10 | Univ Emory | MODIFIED FACTOR VIII |
| AU2002364509A1 (en) * | 2001-11-30 | 2003-06-17 | Emory University | Factor viii c2 domain variants |
| US7105745B2 (en) * | 2002-12-31 | 2006-09-12 | Thomas & Betts International, Inc. | Water resistant electrical floor box cover assembly |
-
2000
- 2000-03-10 US US09/523,656 patent/US6458563B1/en not_active Expired - Lifetime
-
2001
- 2001-02-16 AU AU3841601A patent/AU3841601A/xx active Pending
- 2001-02-16 ES ES01910853T patent/ES2304379T3/es not_active Expired - Lifetime
- 2001-02-16 AU AU2001238416A patent/AU2001238416B2/en active Active
- 2001-02-16 PT PT01910853T patent/PT1280540E/pt unknown
- 2001-02-16 PL PL359672A patent/PL202936B1/pl unknown
- 2001-02-16 NZ NZ520799A patent/NZ520799A/en not_active IP Right Cessation
- 2001-02-16 JP JP2001566673A patent/JP4044337B2/ja not_active Expired - Lifetime
- 2001-02-16 UA UA2002097145A patent/UA75064C2/uk unknown
- 2001-02-16 SK SK1439-2002A patent/SK286205B6/sk not_active IP Right Cessation
- 2001-02-16 WO PCT/US2001/005076 patent/WO2001068109A1/en not_active Ceased
- 2001-02-16 BR BRPI0109131A patent/BRPI0109131B8/pt not_active IP Right Cessation
- 2001-02-16 KR KR10-2002-7011843A patent/KR100485525B1/ko not_active Expired - Lifetime
- 2001-02-16 RU RU2002124123/13A patent/RU2285724C2/ru active
- 2001-02-16 ME MEP-82/09A patent/MEP8209A/xx unknown
- 2001-02-16 EE EEP200200510A patent/EE05075B1/xx active Protection Beyond IP Right Term
- 2001-02-16 CA CA2400295A patent/CA2400295C/en not_active Expired - Lifetime
- 2001-02-16 IL IL15137101A patent/IL151371A0/xx unknown
- 2001-02-16 MX MXPA02008798A patent/MXPA02008798A/es active IP Right Grant
- 2001-02-16 RS YUP-680/02A patent/RS50364B/sr unknown
- 2001-02-16 EP EP01910853A patent/EP1280540B1/en not_active Expired - Lifetime
- 2001-02-16 SI SI200130823T patent/SI1280540T1/sl unknown
- 2001-02-16 CZ CZ20023346A patent/CZ298250B6/cs unknown
- 2001-02-16 HU HU0300586A patent/HU227804B1/hu active Protection Beyond IP Right Term
- 2001-02-16 BR BR122013026957A patent/BR122013026957A8/pt not_active Application Discontinuation
- 2001-02-16 DK DK01910853T patent/DK1280540T3/da active
- 2001-02-16 DE DE60133541T patent/DE60133541T2/de not_active Expired - Lifetime
- 2001-02-16 AT AT01910853T patent/ATE391512T1/de active
- 2001-02-16 CN CNB018063179A patent/CN1191360C/zh not_active Expired - Lifetime
-
2002
- 2002-06-28 US US10/187,319 patent/US7012132B2/en not_active Expired - Fee Related
- 2002-08-21 IL IL151371A patent/IL151371A/en active IP Right Grant
- 2002-08-26 ZA ZA200206810A patent/ZA200206810B/en unknown
- 2002-09-09 NO NO20024296A patent/NO331935B1/no not_active IP Right Cessation
-
2004
- 2004-09-10 US US10/938,414 patent/US7122634B2/en not_active Expired - Fee Related
-
2008
- 2008-07-07 CY CY20081100709T patent/CY1108179T1/el unknown
-
2016
- 2016-04-27 LU LU93049C patent/LU93049I2/xx unknown
- 2016-04-29 FR FR16C0016C patent/FR16C0016I2/fr active Active
- 2016-05-02 BE BE2016C024C patent/BE2016C024I2/fr unknown
- 2016-05-06 LT LTPA2016014C patent/LTC1280540I2/lt unknown
- 2016-05-09 HU HUS1600020C patent/HUS1600020I1/hu unknown
- 2016-05-09 NL NL300808C patent/NL300808I2/nl unknown
- 2016-05-10 CY CY2016011C patent/CY2016011I2/el unknown
- 2016-05-10 NO NO2016007C patent/NO2016007I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2016007I2 (no) | Susoktokog | |
| PT1200105E (pt) | Factor viii modificado | |
| DK1200418T3 (da) | Nematodicide trifluorbutener | |
| DE50012238D1 (de) | Desinfizierendes waschen empfindlicher textilien mit persäuren | |
| DE60101265D1 (de) | Behandlung von augenschmerzen | |
| EA200300717A1 (ru) | Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов | |
| DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
| ATE250605T1 (de) | Piperidin verbindung zur behandlung von psoriasis | |
| MXPA04005079A (es) | Variantes del dominio c2 del factor viii. | |
| CY1106026T1 (el) | Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας | |
| NO20025405D0 (no) | Modulatorer for TNF-alfa-signalisering | |
| DE60121048D1 (de) | PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE | |
| MX9403032A (es) | Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos. | |
| ATE344662T1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
| DE60142786D1 (de) | Zusammensetzungen und methoden zur behandlung von candidosen | |
| CY1105317T1 (el) | Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων | |
| CY1105142T1 (el) | Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων | |
| DE60009315D1 (de) | Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung | |
| ATE390144T1 (de) | Behandlung von fibrosen | |
| MXPA01009174A (es) | Antagonistas de endotelina novedosos derivados de piridazina. |